• Bromodomain Inhibitor, (+)-JQ1: Paradigm Shifts in BET Targe

  2026-05-10

  Explore how Bromodomain Inhibitor, (+)-JQ1 uniquely advances BET bromodomain research in cancer and immunology. Delve into mechanistic breakthroughs, practical assay impact, and emerging applications that distinguish this potent BET bromodomain inhibitor.

• KPT330 Enhances Precision of Cas9 Editing by Regulating mRNA

  2026-05-09

  The referenced study reveals that KPT330, an FDA-approved small molecule, improves the specificity of CRISPR-Cas9 genome and base editing by selectively interfering with the nuclear export of Cas9 mRNA. This work introduces a new class of indirect CRISPR modulators, with important implications for minimizing off-target effects and advancing precision genome engineering in mammalian cells.

• Amyloid β-Peptide (1-42): Microglial Phagocytosis and Ion Ch

  2026-05-08

  Explore how Amyloid β-Peptide (1-42) (Aβ42 peptide) drives microglial phagocytic responses and ion channel modulation in Alzheimer’s disease models. This article offers a deeper mechanistic perspective and practical assay guidance distinct from existing workflow-focused content.

• Nav1.6 Drives Glioblastoma Proliferation via NHE1 and AKT/ER

  2026-05-08

  This study uncovers how voltage-gated sodium channel Nav1.6 promotes glioblastoma cell proliferation and migration by interacting with Na+/H+ Exchanger-1 (NHE1) and activating ERK and AKT survival pathways. Targeting both Nav1.6 and NHE1 offers a promising strategy to inhibit glioblastoma progression and induce apoptosis, providing new avenues for therapeutic intervention.

• Reliable Cell Proliferation and Viability with Cell Counting

  2026-05-07

  This article provides scenario-driven guidance for optimizing cell proliferation, viability, and cytotoxicity assays using Cell Counting Kit-8 (CCK-8), SKU K1018. It addresses laboratory challenges from assay principle to vendor selection, with evidence-based recommendations for maximizing reproducibility and sensitivity in biomedical research workflows.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe Gui

  2026-05-07

  DiI (DiIC18(3)) is a lipophilic fluorescent probe designed for selective plasma membrane labeling in cells and tissues, supporting applications like neuronal tracing and cell migration assays. It should not be used in protocols requiring water solubility or organelle-specific staining, and strict protocol adherence is necessary to avoid loss of signal or non-specific background.

• Nonconventional GLP-1R Antagonist Interplay Mapped by FRET A

  2026-05-06

  This study redefines the selectivity landscape of glucagon and GLP-1 receptor signaling by uncovering unexpected agonist and antagonist interactions at the GLP-1 receptor using high-throughput FRET assays for cAMP. These findings challenge prior assumptions about receptor specificity and inform the design of peptide antagonists for metabolic and type 2 diabetes research.

• Metoprolol in Translational Research: Pharmacodynamics, Anti

  2026-05-06

  Explore how Metoprolol, a selective beta1-adrenoceptor antagonist, advances cardiovascular and cancer biology research by bridging pharmacodynamic action with microenvironmental modulation. This article uniquely examines tissue distribution, anti-inflammatory roles, and assay design, offering practical insights distinct from existing guides.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-05-05

  This study demonstrates that PPARγ activation regulates macrophage polarization, shifting cells from a proinflammatory M1 to an anti-inflammatory M2 phenotype in murine and cell models of inflammatory bowel disease (IBD). These findings clarify the STAT-1/STAT-6 pathway’s role in intestinal inflammation, informing mechanistic approaches in immunometabolic and type 2 diabetes research.

• VX-745: Advancing Translational Research with Dual-Action p3

  2026-05-05

  This article provides translational researchers with a mechanistic and strategic roadmap to leveraging VX-745, a highly selective p38α MAPK inhibitor, for advanced studies in inflammation, cancer, and drug resistance. Integrating recent structural insights and dual-action kinase inhibition, the article delivers actionable protocol guidance and explores how VX-745, available from APExBIO, empowers next-generation research beyond conventional product overviews.

• Structural Mechanisms of ATM Activation by Oxidative Stress

  2026-05-04

  Howes et al. provide the first high-resolution cryo-EM structure of human ATM kinase activated by oxidative stress, revealing disulfide bond-mediated conformational changes that promote substrate engagement and catalytic activation. These insights clarify the molecular basis of redox-dependent signaling in DNA damage and stress response pathways, informing both fundamental biology and translational research.

• Phosbind Acrylamide for Phosphate Signaling: Beyond SDS-PAGE

  2026-05-04

  Explore how Phos binding reagent (Phosbind) acrylamide elevates protein phosphorylation analysis by enabling nuanced detection of signaling changes, without antibodies. This article uniquely bridges mechanistic insights with real-world assay decisions in immunology and virology.

• L-NMMA Acetate: NOS Pathway Modulation for Research Precisio

  2026-05-03

  L-NMMA acetate is a potent, water-soluble inhibitor of all three nitric oxide synthase isoforms, enabling precise modulation of the nitric oxide pathway in biochemical and pharmacological research. APExBIO supplies L-NMMA acetate (SKU B6444) at 98% purity, supporting reproducible investigations into inflammation, cardiovascular, and regenerative signaling. This article details its mechanism, validated applications, and practical workflow integration.

• DMH-1 as an ALK2 Inhibitor: Optimizing Organoid and NSCLC As

  2026-05-02

  Explore how DMH1, a selective ALK2 inhibitor, enables precise BMP pathway modulation for advanced non-small cell lung cancer research and organoid assay optimization. This article reveals practical innovations and methodological insights that set new standards beyond conventional protocols.

• KPT330 Enhances CRISPR-Cas9 Editing Precision via mRNA Expor

  2026-05-01

  This study reveals that KPT330, a selective inhibitor of nuclear export, can improve the specificity of CRISPR-Cas9 genome and base editing by targeting the nuclear export of Cas9 mRNA. By disrupting Cas9 mRNA trafficking rather than Cas9 protein function directly, KPT330 introduces a novel, indirect strategy to minimize off-target effects in gene editing applications.

16667 records 5/1112 page Previous Next 12345 下5页 Last page